News on noninvasive prenatal testing, carrier screening, and preimplantation genetic screening.
The assays quantitatively measure the activity of galactose-1-phosphate uridylyltransferase and biotinidase enzymes from newborn dried blood spot specimens.
Natera reported $94 million in revenues for the quarter, up from $66.8 million a year ago and beating analysts' consensus estimate of $85 million.
The company has identified progesterone metabolites linked to preterm birth and is looking to develop them for predicting risk of delivery prior to 32 weeks.
Illumina had sought to exclude the Harmony test from the US Market, while Ariosa had sought to overturn the jury verdict with a post-trial maneuver.
Revenues for the fiscal year totaled £16.6 million ($20.7 million), up from £8.9 million during FY 2018.
